In an attempt to better understand the impact of BRCA2 mutations on the immune phenotype of prostate cancer, Jenzer and colleagues performed immunohistochemistry and T-cell receptor (TCR) sequencing in nine BRCA2-mutated and nine BRCA wild-type, hormone-sensitive prostate cancers. The gene discussed is BRCA2; the disease is prostate cancer.